At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 66 enrolled
Drug / intervention
moxifloxacin +1 moredrug
Likely dose
moxifloxacin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
In Brief
A Phase 3 clinical trial evaluating moxifloxacin and placebo for Hodgkin Disease and 3 related conditions. Completed, enrolled 66 participants across 1 site.
Detailed Summary
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia. Further investigations include time to occurrence of fever, duration of fever, overall survival and antibiotic sensitivity of blood isolates.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedNov 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.6 years ago
Interventions
moxifloxacindrug
400 mg p.o. per day
placebodrug
one tablet per day p.o.